PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma‐initiating cell properties via DNA methyltransferase 3A-Reference-Cited by-同舟云学术

PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma‐initiating cell properties via DNA methyltransferase 3A

Published:2021-07-16 Issue:1 Volume:16 Page:269-288
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Tanabe Ryo¹²,Miyazono Kohei¹²^ORCID,Todo Tomoki³,Saito Nobuhito⁴,Iwata Caname¹^ORCID,Komuro Akiyoshi¹,Sakai Satoshi¹,Raja Erna¹,Koinuma Daizo¹^ORCID,Morikawa Masato¹^ORCID,Westermark Bengt⁵,Heldin Carl‐Henrik²

Affiliation:

1. Department of Molecular Pathology Graduate School of Medicine The University of Tokyo Japan

2. Department of Medical Biochemistry and Microbiology Science for Life Laboratory Uppsala University Sweden

3. Division of Innovative Cancer Therapy The Institute of Medical Science The University of Tokyo Japan

4. Department of Neurosurgery Graduate School of Medicine The University of Tokyo Japan

5. Department of Immunology, Genetics and Pathology Science for Life Laboratory Rudbeck Laboratory Uppsala University Sweden

Funder

Cancerfonden

Ministry of Education, Culture, Sports, Science and Technology

European Research Council

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13051

Reference58 articles.

1. Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

2. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

3. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

4. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

5. Lomustine and Bevacizumab in Progressive Glioblastoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The TGF-β Family in Glioblastoma;International Journal of Molecular Sciences;2024-01-15

2. Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment;Stem Cell Reviews and Reports;2023-11-03

3. Signaling pathways governing glioma cancer stem cells behavior;Cellular Signalling;2023-01

4. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years;Frontiers in Cell and Developmental Biology;2022-05-25

5. Promising Advances in LINC01116 Related to Cancer;Frontiers in Cell and Developmental Biology;2021-10-14